Steve Harvey/LinkedIn
Sep 19, 2025, 06:06
Aspirin as Precision Medicine? Steve Harvey Highlights Evidence for PIK3-Mutated Colorectal Cancer Patients
Steve Harvey, CEO of Camena Bioscience, shared a post on LinkedIn:
“A very interesting study indicates that Aspirin could be a precision medicine for colorectal cancer.
The study, which was publicised in the New England Journal of Medicine, studied 3500 patients with colorectal cancer.
~40% of those patients had mutations in genes associated with the PIK3 signalling pathway.
Those patients with the PIK3 associated mutations and taking aspirin, were 55% less likely to have the cancer return than those on placebo.
P.s. I’ll add the Guardian article to the comments.”
You can read the full article here.
More posts featured in Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera